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Abstract  
Misuse of recombinant human erythropoietin (rhEPO) is a major concernproblem in 
competitive sports and the implementation development of tests allowing for higher detection 
rates than what current test are capable of is required. In this study a novel lateral flow EPO 
isoform test kit, EPO WGA MAIIA, is evaluated on plasma and urine samples obtained from 
eight healthy malesen in connection with a 28-day rhEPO injection period. During the first 14 
days rhEPO was injected every second day during the first 14 days of the study and the 
method proved to be very effective (xx out of xx) in detecting thisdoping  infor the 
concomitantly obtained samples collected prior to injection. Samples obtained 14 and 21 days 
after the last injection showed no detectable rhEPO. Seven days after the last injection three 
positive (>99.99% CL) subjects were found with the test kit. When using 99% CL as cut-off 
limit, six of the eight subjects (75%) were suspectedfound to be suspicious for doping. 
Samples obtained 14 and 21 days after the last injection showed no detectable trace of rhEPO. 
A previous study using indirect methods to determinefor detecting EPO doping on the same 
samples indicated only that two of the subjects hadwere suspicious valuespositive during 7-21 
days after the last injection.  
We proposesuggest implementing the easy to-use EPO WGA MAIIA rapid lateral flow test as 
an initial screening procedure in anti-doping work to 1) increase the detection rate of potential 
rhEPO doping athletes and 2) allow for analysis of a ten to twenty folds higher analytical rate 
than what is possible todaymore samples than what is possible today.  
 
Keywords: Epoetin beta; erythropoietin; IEF; WGA affinity chromatography.
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Introduction 
Recombinant proteins and peptide hormones such as recombinant human erythropoietin 
(rhEPO) seem to be widely abused in sports to enhance performance [1]. Unfortunately 
the detection of doping with recombinant proteins is difficult [2] since they only possess 
minor structural differences as compared to their endogenous forms. Other challenges 
include that only small concentration of, for example, injected rhEPO is required in 
order to increase exercise performance [3] and the clearance rate from the body is very 
high [4]. Endogenous and recombinant EPOs are glycoproteins that can be 
distinguished by their posttranslational glycosylation pattern, which is specific for the 
synthesizing cell. The basic approach to analytically distinguish between different EPOs 
is to combine electrophoretic or chromatographic separations of EPO isoforms with 
sensitive anti-EPO antibody-based detection methods. Endogenous and recombinant 
EPO glycosylation can be distinguished by charge [5,6], isoelectric point [7], molecular 
mass [8,9] or by interaction with specific lectins [10,11] and the methods are described 
in a recent summary [12]. The methods differ in how well they distinguish certain types 
of glycosylation (the EPO isoform resolution), and by the minimum required amount of 
EPO for the analysis (the EPO detection sensitivity). The methods often require an 
additional purification and/or concentration step before urine and plasma can be 
analysed [13,14]. The isoform methods rely on that large numbers of samples from a 
reference population have been tested to select the most suitable cut-off limits for 
achieving highest possible specificity and sensitivity for detecting a potential doping 
misuse with rhEPO. With the One of the recently presented developed EPO WGA 
MAIIA test kit [11,15,16]EPO isoform methods show quantitative values for EPO 
isoforms are obtained, the EPO WGA MAIIA test kit [11,15,16], by using percentage of 
migrated isoforms (PMI) as unit. Quantification allows the use of confidence limits 
(CL) calculated from the results for the reference population, and makes between 
method comparison possiblepossible. imprecision studies and comparison with other 
methods.  
Hence, tThe detection of potential rhEPO doping by athletes is hence very challenging 
[17,18,19,20,21,22] and with the present study we hope to increase the efficacy hereof. 
The newly developed EPO WGA MAIIA method is suggested to be much more sensitive than 
the IEF method currently appliedused by the World Anti Doping Agency (WADA) to fight 
EPO doping laboratories today. In samples collected from a major sport event the method 
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determined 6% to be positive whereas the IEF method did not flag one sample to be indicative 
of EPO doping [11].  
This study evaluates the efficiency to detect potential rhEPO abuseabuse in plasma and urine 
samples obtained from volunteers injected with rhEPO. Based on the potentialhypothesized 
higher sensitivity, we expectedhypothesize that the MAIIA method would proves superior as 
compared to other methods in their ability to determine EPO doping.  
Feldfunktion geändert
Feldfunktion geändert
Formatiert: Schriftart: 12 Pt.
  5 
Methods 
Samples collected in the rhEPO injection study.  
Urine and blood plasma samples were obtained from a recently performed study [17]. Briefly, 
all samples were obtained from eight healthy male volunteers (23 ± 3 years) before, during 
and after ten s.c. injections of 5,000 IU (65 IU ± 5/kg bodyweight) of NeoRecormon®. This 
pharmaceutical glycoprotein belongs to the group epoetin beta. The samples were collected 
before (-14, -10) and 2 days after injection during day 2-16, and finally 7, 14 and 21 days 
after injection at day 35, 42 and 49. The injection and collection regime is illustrated in Fig. 1. 
 
Reference population urine and plasma samples.  
Urine samples from 25 healthy volunteer donors (men and women between 20 and 60 years 
of age) were collected after approval by the local ethical committee (No. 2005:307), and 
combined with 8 pre-samples from the injection series to establish the reference values for   
EPO WGA MAIIA. The 16 plasma pre-samples from the injections series and 7 additional 
EDTA plasma samples (leftovers from a routine medical health check-up) were used as 
reference plasma samples. All specimens were stored in aliquots at -20ºC until analysed. 
 
Affinity purification of EPO prior to MAIIA test.  
EPO from 0.4 mL of plasma and 5 mL urine samples was purified according to the 
instructions from the producer (EPO Purification Kit, MAIIA Diagnostics, Uppsala, Sweden). 
The EPO affinity purification recovery was 62.5% for the 85 plasma samples and 39% for the 
67 urine samples. The EPO concentration in urine, plasma and purified sample was 
determined using a commercially available kit (EPO Quantification Kit, MAIIA Diagnostics). 
The affinity purification kit has been evaluated recently [13,14]. Following this procedure it 
took 20 min to obtain affinity purified and concentrated EPO samples from 5 mL of urine. 
 
The MAIIA isoform analysis.  
A MAIIA kit (EPO WGA MAIIA prototype Kit, MAIIA Diagnostics) was used to analyse 
affinity purified EPO from urine or plasma samples in accordance with the instructions from 
the supplier. The procedure, standardization and scanner equipment have been described 
recently [11]. The MAIIA lateral flow strip contains both a WGA (wheat germ agglutinin) 
lectin zone and downstream from this, an anti-EPO zone. Briefly, after immersing the strip in 
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a well containing the sample, all EPO is bound in the first tenth of the 8 mm long WGA zone. 
Then the strip is moved to a second well for desorption of EPO, from its WGA interaction, by 
a WGA competing sugar derivate, N-acetylglucosamine (GlcNAc). Two strips were used to 
obtain total (using high concentration of GlcNAc, 100 mM) desorption and two strips were 
used for retarded (using low 10 mM of GlcNAc) desorption of EPO for each sample. 
Desorption from the WGA binding starts the migration of EPO and the most rapidly 
migrating ones can pass the WGA zone and be captured in the subsequent anti-EPO zone on 
the strip. Desorption was interrupted after 5 min. by removing the WGA zone by cutting. EPO 
bound to the anti-EPO zone was reacted with anti-EPO bound to carbon black nano-string, 
and the obtained grey to black signal intensity was quantified with an image scanner and 
compared to the signal obtained for an rhEPO standard. The unit PMI (Percentage of 
Migrated Isoforms) was obtained by calculating [EPO amount released during retarded 
conditions using 10 mM GlcNAc]/[total amount of EPO released using 100 mM GlcNAc] x 
100. It took about 30 min to obtain the results from one test run. 
 
Determination of EPO concentration in urine using lateral flow immunoassay.  
The method, combining desalting and quantification using EPO Quantification Kit, has been 
presented elsewhere [23]. 
 
Determination of EPO concentration in plasma using lateral flow immunoassay.  
EPO Quantification Kit (MAIIA Diagnostics) was used in accordance with the instructions 
from the supplier, but some additional steps were required for the plasma measurement. The 
plasma samples were diluted 8 times in a 20 mM phosphate buffer pH 7.5, supplemented with 
6% BSA, 0.1 M NaCl and 0.02% NaN3. In each well 25 µl of diluted sample was mixed with 
25 µl of 20 mM phosphate buffer pH 7.5 supplemented with 1% BSA, 0.1 M NaCl, 0.1% 
bovine gamma globulin, 0.02% monoclonal mouse IgG, 1% Tween 20 and 0.05% NaN3. 
0.02% monoclonal mouse IgG was added to the working solution of anti-EPO carbon black 
nano-strings. 
 
Statistics.  
Values are presented as means ± SD. Differences in results for the groups before and after 
administration of drug were examined by paired t-test (SigmaPlot 12, Systat Software, USA) 
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after normal distribution control using Shapiro-Wilk test. Statistical significance was accepted 
at P <0.05 (*), P <0.01 (**) and P <0.001 (***). 
Each individual result before and after administration of the drug was also compared to the 
one-tailed confidence limit (CL) calculated from the results for the reference population. 
Limits selected at 99.99%, 99.9%, 99.0% and 97.8% allow that 0.1, 1, 10 or 22 normal 
samples out of 1000 samples are outside the limit, and regarded as aberrant. 
Formatiert: Schriftart: (Standard)
Times New Roman, 12 Pt., Nicht
Fett
  8 
Results 
EPO WGA MAIIA results during the boosting, maintenance and wash out period 
Eight subjects were each administrated with ten s.c. doses of 5,000 IU epoetin beta (65 IU ± 
5/kg) and the injection regime and results are shown in Fig. 1. The EPO WGA MAIIA 
isoform analysis demonstrated a highly significant (P<0.001) change in values between the 
pre treatment samples (day -14) and the samples collected 2 days after injection at day 2-16 
for both plasma (panel A) and urine samples (panel B). The plasma samples collected on day 
35, 7 days after last injection (n=7), showed significantly (P=0.041) decreased values 
compared to pre treatment values for the isoform test. The results for the urine samples (n=6) 
collected the same day were highly significantly (P=0.005) decreased compared to samples 
collected on day -14. The results at14 and 21 days after last injection could not be 
distinguished from pre treatment sample results.  
 
Plasma and urine EPO concentration during the test period 
The plasma and urine EPO concentration was determined by the EPO lateral flow 
immunoassay and is shown in Fig. 1. For the 16 plasma samples collected before any 
injection, at days -14 and -10, the EPO concentration was 99.9 ± 43.2 ng/L, while the 
concentration increased significantly (P<0.001) to 300 ± 90.5 ng/L for the 47 samples 
collected on days 2 to 16, two days after previous injection. The individual mean plasma EPO 
concentrations were in the range 240-396 ng/L for the eight subjects during days 2-16. The 
urine EPO concentration was 20.4 ± 13.1 ng/L for the eight samples collected before injection 
and 72.9 ± 71 ng/ L at days 2 to 16, collected two days after previous injection. As expected 
Aa considerable variability in the urine EPO concentration was present, as expected.  
At day 35 it can be noticed that the total concentration of EPO had returned to normal values, 
while the EPO WGA MAIIA values still can shows presence of epoetin beta. 
 
Analysis of samples to obtain the reference range 
The analysis of the reference samples revealed 73.0 ± 6.5 PMI for the 33 urine specimens, 
with a range from 61.8 to 87.0 PMI. The 97.8, 99.0, 99.9 and 99.99% CL values were 58.9, 
56.1, 49.7 and 44.4 PMI, respectively. For the 23 plasma samples the mean value was 75.7 ± 
8.4 PMI, with a range from 62.8 to 92.1 PMI. The 97.8, 99.0, 99.9 and 99.99% CL values 
were 60, 57.8, 52.8 and 48.7 PMI, respectively.  
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The PMI values can be compared to affinity purified recombinant epoetin beta that gave 
PMI’s of 26.6 ± 2.1 and 24.9 ± 2.0 when used as controls for the presented urine (n=13) and 
plasma (n=8) test runs, respectively.  
 
Imprecision for the EPO WGA MAIIA 
In each test run, three control preparations were included containing 1) affinity purified 
endogenous EPO in urine from one healthy subject 2), affinity purified epoetin beta applied to 
buffer, and 3) a known mixture of 60% endogenous and 40% of epoetin beta. The inter-assay 
CV was 8.2% when tested on 21 different test occasions for the three controls between 25 to 
77 PMI.  
The immunoassay measurement for retarded and total desorption mode demonstrated a 
median coefficient of variation (CV) of 4.7% between the duplicates when 603 samples from 
the injection series, the reference samples, and several controls were measured.  
 
Comparing plasma and urine sample analysis    
In order to reveal if the detectability of epoetin beta is different in plasma and urine samples, 
the results for plasma and urine samples collected on days -14, 16 and 35 are shown in Fig. 2.  
All samples collected on day 16, 2 days after the last injection, were clearly outside the 
99.99% CL. The samples collected on day 35, 7 days after the last injection, were the most 
interesting ones for sensitivity comparison, as the method seemed close to its doping detecting 
limit. For the 5 subjects having both urine and plasma results it was found that one plasma 
sample and four urine samples were outside the 99.0% CL. This indicates that the analysis of 
urine samples gives a slightly wider detection window than plasma samples.  
 
The MAIIA results for each subject at day 35, 7 days after last injection  
The individual EPO WGA MAIIA values, haemoglobin and haematocrit values at day 35 are 
givenfound in Tab.1. In total 7 plasma samples from day 35 were analysed, and one of these 
was outside 99.99% CL, but unfortunately the corresponding urine sample for that specific 
sample was not available. There were 6 urine samples available for analysis from that 
particular day and two of them where outside 99.99% CL.  
By combining the MAIIA results for plasma and urine collected on day 35, results for all 
eight subjects were obtained. Three of the eight subjects (38%) showed results outside the 
99.99% CL while 75% (6/8) was outside the 99.0% CL. The haemoglobin and haematocrit 
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values were exceeding the limit [24] of 170 g/L and 50 %, respectively, for only one of the 
subjects, who would have been excluded from starting competition. This subject had also a 
haematocrit value above the limit (50.5%) at day 42, 14 days after last injection. Subject 16 
had a haematocrit value of 50.4% at day 49, 21 days after last injection, which would have 
excluded him. In nNone of the other testingsampling days were the limits were exceeded for 
any of the subjects.   
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Discussion 
The present study evaluateds the detection efficiency of a novel lateral flow isoform test, EPO 
WGA MAIIA, intended for EPO anti-doping control, on samples collected before, during and 
after s.c. injections with epoetin beta in eight healthy menales. The main finding is that the 
EPO WGA MAIIA method can measuredetermine rhEPO injections doping during a 14 day 
period with a high injection rate the boosting and also up to 7 days after a period with less 
frequent injectionsmaintenance period up to 7 days after last injection, but not at 14 days. It is 
also indicated that urine is a better specimen than plasma for doping analysis.    
Results were available for all eight subjects on day 35, 7 days after last injection, only by 
combining results from urine and plasma samples. This revealed that three out of eight 
subjects were outside the 99.99% CL, and thus 38% of the subjects were regarded as positive 
for EPO doping. Additional three subjects (38%) exceeded the 99.0% CL, but not 99.9%. 
Only two subjects were negative for doping (25%).     
 
Other tests performed on the samples collected from the presented injection  study 
The urine samples collected from the same injection series was analysed during 2007 by 
means of IEF in a previois publication [17] and demonstrated 2 out of 7 (33%) tested samples 
as positive on day 35.  
The use of indirect methods [25] to identify EPO doping for the samples from the study 
presented herein, has also been presented elsewhere [26]. During the entire 49 days sample 
collection period very few of the eight subjects exceeded the cut-off limit (99.9% CL) for 
OFFz score (two subjects), percentage of reticulocytes (two subjects), Hbz score (one subject) and 
OFFhr score (no subjects). The limit for percentage of reticulocytes was exceeded once for two 
subjects, and only during the injection period where all eight subjects were found to be 
positive with EPO WGA MAIIA. OFFz score showed one subject outside the 99.9% CL on 
days 35 and 42, while another subject was outside the limit at day 49.  
Aerobic exercise capacity was significantly increased on days 35, 42 and 49 [17], with the 
peak value determined on day 42. During these days, 7-21 days after the last injection, three 
subjects were positive (99.99%) and another three subjects were suspicious (99.0%) for 
doping using EPO WGA MAIIA, while only two subjects exceeded the 99.9% limit with 
OFFz score. The EPO WGA MAIIA test, which identified rhEPO both during and up to 7 days 
after injection, and indirect test, which in this study indicated misuse 7 to 21 days after last 
injection, seems preferable to use in combination.   
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Detection of different types of rhEPO  
In this study the ability for isoform methods to detect injections specifically with epoetin beta 
was studied. An optimal EPO doping control method should be able to distinguish all 
different recombinant EPOs and all available EPO-like molecules [22,27,28] from the at least 
two to three different endogenous EPO populations. The EPO WGA MAIIA method has 
previously proven to be successful in the detection of several isoforms of EPO [11] like 
epoetin alpha, omega, delta, darbepoetin alpha and CERA. The method has also successfully 
been identifying identified the injection of epoetin- alpha and darbepoetin alpha in horses 
[15]. 
EPO WGA MAIIA has also been used for detecting intravenous administration of epoetin 
beta 72h after last injection.    
 
The minimal required amount of rhEPO that can be detected 
The EPO detection sensitivity of the isoform method seems sufficient to distinguish isoforms 
of rhEPO in urine samples containing as little as 0.1 to 1 ng/L (3 to 30 femtomol) of EPO. 
This is crucial since very low EPO concentrations were found in several urine samples 
collected during a major competition [11]. The MAIIA method was able to determine that 
these samples had aberrant EPO forms while the EPO amount was too low for IEF analyses. 
In the present study the MAIIA method analysed all samples were analysed using only 5 mL 
urine for affinity purification as compared to the 20 mL required for IEF doping method. It 
was calculated that even 2.5 mL of urine had been sufficient for analysis of all the samples in 
the series.  
The increased sensitivity may be due to better detection sensitivity as well as to the high EPO 
recovery of the affinity purification regime required prior to the isoform test procedure.  
Conclusion.  
The sensitive and easy-to-use MAIIA method with a process time of just 1 hour, and with 
potential for large-scale testing seems to be a very good candidate for a screening tool against 
EPO doping. This test demonstrated a higher detection rate than the other direct and indirect 
EPO doping tests that were tested on the samples from the presented epoetin beta injection 
series.  
The on-going EPO doping in sport needs to be stopped [1].Todays acknowledged methods to 
determine EPO doping are unfortunately not as efficient as could be whished for. Furthermore 
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the analytical procedures are not easy to perform and very expensive. In the present study it is 
proposed that the inclusion of an affordable and sensitive screening test against rhEPO doping 
will lead to higher detection rates than what is seen today. Moreover, the use of quantitative 
results for isoform tests could allow the implementation of different degrees of 
suspiciousness. Exceeding a certain limit is suggested to lead to an intense out-of-competition 
sampling program.  
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.
  14 
Acknowledgements  
The authors thank Malin Drevin, Mikael Lönnberg, and Trikien Quach for technical 
assistance. The authors are grateful for the financial support for the development of the 
MAIIA test from VINNOVA (The Swedish Governmental Agency for Innovation Systems) 
in the project P25917. 
Formatiert: Schriftart: 12 Pt., Fett
Formatiert: Schriftart: 12 Pt.
  15 
References 
[1] C. Lundby, P. Robach, and B. Saltin, The evolving science of detection of 'blood doping'. 
Br. J. Pharmacol. 165 (2012) 1306-15. 
[2] O. Barroso, I. Mazzoni, and O. Rabin, Hormone abuse in sports: the antidoping 
perspective. Asian journal of andrology 10 (2008) 391-402. 
[3] C. Lundby, P. Robach, R. Boushel, J.J. Thomsen, P. Rasmussen, M. Koskolou, and J.A. 
Calbet, Does recombinant human Epo increase exercise capacity by means other than 
augmenting oxygen transport? J. Appl. Physiol. 105 (2008) 581-7. 
[4] C.E. Halstenson, M. Macres, S.A. Katz, J.R. Schnieders, M. Watanabe, J.T. Sobota, and 
P.A. Abraham, Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and 
epoetin beta. Clin. Pharmacol. Ther. 50 (1991) 702-12. 
[5] L. Wide, and C. Bengtsson, Molecular charge heterogeneity of human serum 
erythropoietin. Br. J. Haematol. 76 (1990) 121-7. 
[6] L. Wide, C. Bengtsson, B. Berglund, and B. Ekblom, Detection in blood and urine of 
recombinant erythropoietin administered to healthy men. Med. Sci. Sports Exerc. 27 (1995) 
1569-76. 
[7] F. Lasne, L. Martin, N. Crepin, and J. de Ceaurriz, Detection of isoelectric profiles of 
erythropoietin in urine: differentiation of natural and administered recombinant hormones. 
Anal. Biochem. 311 (2002) 119-126. 
[8] M. Kohler, C. Ayotte, P. Desharnais, U. Flenker, S. Lüdke, M. Thevis, E. Völker-
Schänzer, and W. Schänzer, Discrimination of Recombinant and Endogenous Urinary 
Erythropoietin by Calculating Relative Mobility Values from SDS Gels. Int. J. Sports Med. 
29 (2008) 1-6. 
[9] C. Reichel, R. Kulovics, V. Jordan, M. Watzinger, and T. Geisendorfer, SDS-PAGE of 
recombinant and endogenous erythropoietins: benefits and limitations of the method for 
application in doping control. Drug Test Anal 1 (2009) 43-50. 
[10] L. Franco Fraguas, J. Carlsson, and M. Lönnberg, Lectin affinity chromatography as a 
tool to differentiate endogenous and recombinant erythropoietins. J. Chromatogr. 1212 (2008) 
82-88. 
[11] M. Lönnberg, M. Andren, G. Birgegard, M. Drevin, M. Garle, and J. Carlsson, Rapid 
detection of erythropoiesis-stimulating agents in urine and serum. Anal. Biochem. 420 (2012) 
101-114. 
[12] C. Reichel, Recent developments in doping testing for erythropoietin. Anal. Bioanal. 
Chem. 401 (2011) 463-81. 
[13] Y. Dehnes, S. Lamon, and M. Lonnberg, Erythropoietin (EPO) immunoaffinity columns-
-a powerful tool for purifying EPO and its recombinant analogues. J. Pharm. Biomed. Anal. 
53 (2010) 1028-32. 
[14] M. Lönnberg, Y. Dehnes, M. Drevin, M. Garle, S. Lamon, N. Leuenberger, T. Quach, 
and J. Carlsson, Rapid affinity purification of erythropoietin from biological samples using 
disposable monoliths. J. Chromatogr. A 1217 (2010) 7031-7. 
[15] M. Lonnberg, U. Bondesson, F. Cormant, P. Garcia, Y. Bonnaire, J. Carlsson, M.A. 
Popot, N. Rollborn, K. Rasbo, and L. Bailly-Chouriberry, Detection of recombinant human 
EPO administered to horses using MAIIA lateral flow isoform test. Anal. Bioanal. Chem. 403 
(2012) 1619-28. 
[16] M. Ashenden, K. Sharpe, A. Garnham, and C.J. Gore, Evaluation of the MAIIA dipstick 
test to detect recombinant human erythropoietin in plasma. J. Pharm. Biomed. Anal. 67-68 
(2012) 123-8. 
Formatiert: Schriftart: 12 Pt., Fett
Formatiert: Schriftart: 12 Pt.
Feldfunktion geändert
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
  16 
[17] C. Lundby, N.J. Achman-Andersen, J.J. Thomsen, A.M. Norgaard, and P. Robach, 
Testing for recombinant human erythropoietin in urine: problems associated with current anti-
doping testing. J. Appl. Physiol. 105 (2008) 417-9. 
[18] F. Lasne, L. Martin, J.A. Martin, and J. de Ceaurriz, Isoelectric profiles of human 
erythropoietin are different in serum and urine. Int. J. Biol. Macromol. 41 (2007) 354-357. 
[19] S. Lamon, N. Robinson, P.-E. Sottas, H. Henry, M. Kamber, P. Mangin, and M. Saugy, 
Possible origins of undetectable EPO in urine samples. Clin. Chim. Acta 385 (2007) 61-66. 
[20] S. Lamon, L. Martin, N. Robinson, M. Saugy, J. Ceaurriz, and F. Lasne, Effects of 
exercise on the isoelectric patterns of erythropoietin. Clin. J. Sport Med. 19 (2009) 311-5. 
[21] M. Beullens, J.R. Delanghe, and M. Bollen, False-positive detection of recombinant 
human erythropoietin in urine following strenuous physical exercise. Blood 107 (2006) 4711-
3. 
[22] W. Jelkmann, Novel Erythropoietic Agents: A Threat to Sportsmanship. Medicina 
Sportiva 11 (2007) 32-42. 
[23] M. Lönnberg, M. Drevin, and J. Carlsson, Ultra-sensitive immunochromatographic assay 
for quantitative determination of erythropoietin. J. Immunol. Methods 339 (2008) 236-244. 
[24] M. Zorzoli, Blood monitoring in Anti-Doping Setting. Recent Advances in Doping 
Analysis 13 (2005) 255-264. 
[25] K. Sharpe, M.J. Ashenden, and Y.O. Schumacher, A third generation approach to detect 
erythropoietin abuse in athletes. Haematologica 91 (2006) 356-63. 
[26] A. Borno, N.J. Aachmann-Andersen, T. Munch-Andersen, C.J. Hulston, and C. Lundby, 
Screening for recombinant human erythropoietin using [Hb], reticulocytes, the OFF(hr score), 
OFF(z score) and Hb(z score): status of the Blood Passport. Eur. J. Appl. Physiol. 109 (2010) 
537-43. 
[27] S.E. Franz, Erythropoiesis-stimulating agents: development, detection and dangers. Drug 
Test Anal 1 (2009) 245-9. 
[28] I.C. Macdougall, and M. Ashenden, Current and upcoming erythropoiesis-stimulating 
agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis 16 
(2009) 117-30. 
 
 
 
 
 
 
 
 
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
Formatiert: Schriftart: 12 Pt.,
Nicht Fett
  17 
Fig. 1. EPO WGA MAIIA and total EPO concentration results   
Subjects were s.c. injected with epoetin beta 10 times ( ) i.e. day 0, 2, 4, 6, 8, 10, 12, 14, 21 
and 28. Samples for analysis were obtained prior to the rhEPO injections and then two days 
after each injection. Finally, samples were obtained on day 35, 42 and 49, corresponding to 7, 
14, and 21 days after the last rhEPO injection. Directly two days after the first injection the 
epoetin beta concentration in plasma and urine was increased and the EPO WGA MAIIA 
values were significantly reduced, indicating doping. Seven days after last injection EPO 
WGA MAIIA significantly detects rhEPO in the urine and plasma samples while the EPO 
concentration is back in the normal range. At 14 and 21 days after last injection the EPO 
WGA MAIIA values are normal. 
Significant difference, as compared to the pre-EPO (day -14) values, is indicated with: 
*=P<0.05, **=P <0.01, ***=P <0.001. 
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Fig. 2.  EPO WGA MAIIA analysed with plasma and urine samples  
The samples collected at day 16, 2 days after last injection, are all well outside the 99.99% CL 
for both urine and plasma. The interesting day for comparing test sensitivity is day 35, 7 days 
after last injection. For the five subjects having both urine and plasma samples it was found 
that one plasma samples and four urine samples were outside the 99% CL and regarded as 
doping suspected samples. This indicates that traceable amounts of epoetin beta remain in 
urine, while excreted from plasma, at 7 days after last injection.  
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Tabel 1 
The table shows the individual EPO WGA MAIIA values, and haemoglobin and haematocrit 
values, for each of the eight subjects on day 35, 7 days after last injection. As not all of the 
samples were available for testing both the plasma and urine results are used to settle the 
suspicions for doping. Three of the subjects will be positive for doping (10,11,13) being 
outside the 99.99% CL. Three of the subjects might be suspected for doping (9, 12,15) being 
outside the 99% CL, while only two subjects are negative (25%). The haemoglobin and 
haematocrit values exceed the limits for competition exclusion only for one subject (13). 
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